Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia
- 1 September 2005
- journal article
- Published by Elsevier BV in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 122 (1), 33-39
- https://doi.org/10.1016/j.ejogrb.2004.11.015
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal–fetal interface in the mouse placentaProceedings of the National Academy of Sciences of the United States of America, 2003
- Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces ProteinuriaPublished by Elsevier BV ,2003
- Recent Insights into the Pathogenesis of Pre-eclampsiaPlacenta, 2002
- Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets SyndromeThe American Journal of Pathology, 2002
- Birthweight by gestational age in NorwayActa Obstetricia et Gynecologica Scandinavica, 2000
- Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre‐eclampsiaBJOG: An International Journal of Obstetrics and Gynaecology, 1999
- Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre‐eclampsiaBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre‐eclampsiaEuropean Journal of Clinical Investigation, 1996
- Elevated serum levels of vascular endothelial growth factor in patients with preeclampsiaObstetrics & Gynecology, 1995